Acadia Pharmaceuticals (ACAD) announced that Thomas Andrew Garner has been appointed Chief Commercial Officer, effective today. Mr. Garner will spearhead Acadia’s commercial strategy and operations, driving the Company’s plans for sustained growth and expansion of its product portfolio and pipeline across U.S. and international markets. Mr. Garner will report to Catherine Owen Adams, Acadia’s CEO, and serve on the executive leadership team. “Tom is an accomplished commercial executive with a demonstrated history of driving brand growth across a wide range of therapeutic areas and global businesses,” said Catherine Owen Adams, CEO. “His experience includes a breadth of successful brand launches, including those in neuropsychiatric and rare cardiac diseases. We are thrilled to welcome him into this pivotal commercial leadership role as we continue our launch of DAYBUE in the US, while also preparing for launches outside the U.S and building a strong foundation for the potential introduction of new therapies in the future.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ACAD:
- Biotech Alert: Searches spiking for these stocks today
- Acadia announces exclusive license agreement with Saniona for SAN711
- Acadia Pharmaceuticals Announces Leadership Change Amid COO Departure
- Acadia Pharmaceuticals price target lowered to $32 from $33 at Canaccord
- Acadia Pharmaceuticals participates in a conference call with JPMorgan
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
